| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -17.9 | -18.2 |
| EPS (diluted, $ a share) | $-0.42 | $-0.47 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: ACRV. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Acrivon Therapeutics, Inc.: key numbers
- Share price
- $1.43Close, Nov 17
- Market cap
- $61.4M
- Shares outstanding
- 42.91MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Acrivon Therapeutics, Inc.
All →Acrivon Therapeutics Financial Results
Acrivon Therapeutics reported Q3 2026 financial results, ending the period with $77.8 million in cash and marketable securities, which is expected to fund operations into Q4 2027. The company highlighted its strategic expansion into immunology and inflammation (I&I) with the acquisition of ACR-525 and provided updates on its clinical pipeline, including upcoming Phase 2b interim data for ACR-368.
- Term
- Q3 2026
“We have had transformative progress this year, including the strategic expansion into immunology and inflammation and the positive clinical results in tumor types predicted sensitive by AP3 to our internally developed, first-in-class WEE1/PKMYT1 inhibitor ACR-2316, laying the foundation for multiple upcoming value-inflection milestones.”
Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and co-founder of Acrivon
Acrivon Therapeutics Investor Presentation
Acrivon Therapeutics hosted a corporate R&D event and webcast featuring Key Opinion Leaders to introduce its new immunology and inflammation (I&I) programs, ACR-525 and a PKCθ inhibitor. The company filed a formal investor presentation deck detailing the preclinical programs and development plans for Eosinophilic esophagitis (EoE) identified via its AP3 platform.
Acrivon Therapeutics M&A Deal with Aqilion AB
Acrivon Therapeutics has acquired a portfolio of immunology and inflammation (I&I) assets from Swedish biotech Aqilion AB, including the Phase 2-ready oral JAK1 inhibitor ACR-525 and a preclinical PKCθ inhibitor program. The deal establishes I&I as a new strategic pillar for Acrivon, which plans to apply its AP3 precision medicine platform to these assets for indications such as Eosinophilic esophagitis (EoE).
- Counterparty
- Aqilion AB